Group 1: Industry Trends - The CXO industry in China is experiencing a recovery driven by increased demand for outsourced research and production services, with significant growth expected in 2026-2027[5] - The global CXO market is projected to grow from $197 billion in 2024 to $298 billion by 2030, representing a compound annual growth rate (CAGR) of 7%[10] - The trend of Chinese innovative drugs going global is expected to create long-term opportunities for CXO companies, enhancing their order and pricing power[16] Group 2: Investment Recommendations - BOCOM International recommends focusing on high-quality, cost-effective leaders in the CXO sector, specifically WuXi AppTec, Kelun Pharmaceutical, and Kanglongda, all rated as "Buy"[24] - WuXi AppTec is highlighted for its strong order performance and expected revenue growth, with a target price of HKD 91, indicating a potential upside of over 60%[25] - Kelun Pharmaceutical is expected to see a revenue CAGR of 16% from 2025 to 2027, with a target price of HKD 113.8, suggesting a potential upside of over 50%[25] Group 3: Key Drivers of Growth - The expansion of demand for innovative drug development and production outsourcing is a key driver for the CXO industry, with significant increases in R&D investments expected[9] - The integration of AI in drug development is anticipated to reach a critical development point in 2026, enhancing decision-making in early-stage research[9] - The industry is witnessing a trend of consolidation, where leading companies are acquiring smaller firms to enhance their technological capabilities and market presence[14] Group 4: Risks and Challenges - Potential risks include mismatches in supply and demand, particularly in new molecular types and regulatory challenges in overseas markets[5] - The increasing complexity of global supply chains and regulatory requirements may pose challenges for CXO companies lacking international experience[21] - The industry faces uncertainties related to drug pricing reforms and geopolitical factors that could impact operational stability[12]